Contract manufacturing for pharma – discover top companies' revenue prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.
Our study analyses 30 leading CMOs. There you discover how revenues from drug production services can increase.
That way you find information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.
Forecasts and other data to help you stay ahead
In our new study you find analytical profiles of 30 top companies, and analyses of the overall industry. You discover historical data, market shares, revenue forecasts, and growth rates. See, too, qualitative analysis, business outlooks and developments.
There you also gain 141 tables, 58 charts, and five interviews with the industry.
Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in knowledge of the CMO industry and market:
• Finished dosage formulations (FDF) manufacturing
• Active pharmaceutical ingredients (API) production.
See now how you can benefit your research, analyses and decisions, also saving time. The following sections highlight what you find in our new investigation.
Company profiles – activities, results, competition, and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the company. In general, though, a profile gives you the following information:
• Overview of the company's contract manufacturing services, including clients
• Analysis of recent financial performance – overall revenue and that for CMO services
• Assessment of developments – acquisitions, capacity expansions, new service offerings, and collaborations
• SWOT analysis of the company – strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2013 to 2023
• Forecasting of pharmaceutical contract manufacturing revenues to 2023, for 23 of the companies
• Transcript of an interview by Visiongain, for five of the companies.
Discover there what participants achieve, do, and say, helping you stay ahead.
European contract manufacturing organisations
First, our study gives you discussions, financial analyses, and commercial outlooks for 15 European CMOs, including these:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim Biopharmaceuticals
• Famar
• Fareva
• Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2023.
Companies based in the US and Japan
Next, our report shows you developments and sales outlooks to 2023 for five other companies:
• Catalent Pharma Solutions
• Patheon
• AbbVie Contract Manufacturing
• Daito Pharmaceutical
• Pfizer CentreSource.
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. You see where prospects exist.
Developed-market API specialists
You also discover outlooks for four top producers of active pharma ingredients:
• Teva API
• Esteve Química
• Euticals
• Cambrex.
Our report shows you potentials of the industry. You see possibilities for advancing technology and raising business performance.
India and China – analysis of pharma manufacturing service providers
Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
• Dr. Reddy's Laboratories
• Aurobindo Pharma
• Divis Laboratories
• Shandong Xinhua Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, seeing what the present and future hold.
Predictions for the worldwide pharma CMO market and submarkets
Our report also forecasts revenues to 2023 for the world contract manufacturing industry and its main segments: APIs and FDFs.
There you see overall world revenues in 2017 reaching $66.4bn. Our analyses reveal high growth from 2013 to 2023. That work also predicts large companies and specialty healthcare firms will develop and prosper. She how and where, finding potential.
Biologics and biosimilars also hold promise. New biological therapies – including antibody-drug conjugates and regenerative medicines – interest CMOs and clients.
Discover opportunities and revenue predictions, then, for outsourced production of medicines. You investigate established and rising companies, finding their prospects.
Six ways Pharma Leader Series: Top Pharma Contract Manufacturing Organisations (CMOs) 2013-2023 helps you
In particular, our new investigation gives you the following knowledge:
• Revenues to 2023 for the world CMO market and its components – discover that industry's prospects, finding promising places for investments and revenues
• Profiles of 30 leading companies – assess services, strategies, sales results and outlooks, also gaining revenue forecasts to 2023 for 23 of the organisations
• Interviews with 5 companies in the CMO industry – discover debates and opinions to help you stay ahead
• Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages
• Outlooks for established players and firms entering the sector – explore needs, practices, and outlooks for future success.
Information found nowhere else
That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.
With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
Prospects for pharma manufacturing providers – gain by ordering now
Our study lets you find data, trends, opportunities, and commercial predictions for outsourced drug and API production. Avoid missing out – please order our new report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here
1. Executive Summary
1.1 Pharma Contract Manufacturing Market Leaders: Overview 2013
1.2 Report Contents
1.2.1 Company Profile Contents
1.2.2 Company Revenue Forecasting
1.3 Research and Analysis Methods
2. An Introduction to the Pharma Contract Manufacturing Market 2013
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 The Are Benefits to Outsourcing
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market 2012
2.2.1 Where Are Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharma Contract Manufacturing Market 2013-2023
2.3.1 Pharma Contract Manufacturing: Market Drivers 2013-2023
2.3.2 Pharma Contract Manufacturing: Market Restraints 2013-2023
2.4 Who Are the Leading Pharma Contract Manufacturers in 2013?
3. Leading European Contract Manufacturing Organisations 2013
3.1 Lonza
3.1.1 Lonza Is a Leader in Biologics Manufacturing
3.1.2 Lonza Custom Manufacturing: Steady Decline in Revenue 2008-2012
3.1.3 Investing in Advanced Biological Drug Sectors
3.1.3.1 The Promise of Antibody-Drug Conjugates (ADCs)
3.1.4 Lonza and Regenerative Medicine
3.1.5 Lonza: SWOT Analysis 2013-2023
3.1.6 Biologics Will Drive Revenue Growth for Lonza 2013-2023
3.2 Evonik Degussa
3.2.1 Evonik Offers API and Formulation Services
3.2.1.1 Evonik Is a HPAPI Specialist
3.2.2 Evonik Continues to Grow Across All Sectors
3.2.3 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.2.4 Evonik Degussa: Outlook to 2023
3.3 Royal DSM
3.3.1 DSM Pharmaceutical Products: Manufacturing Services
3.3.1.1 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.3.2 DSM Pharmaceutical Products: Financial Performance 2008-2012
3.3.3 Investing in Biopharmaceutical Manufacturing
3.3.4 Expanding API Manufacturing
3.3.5 Generics Are an Opportunity for Growth 2013-2023
3.3.6 DSM Pharmaceutical Products: Revenue Forecast 2013-2023
3.4 Boehringer Ingelheim Biopharmaceuticals
3.4.1 Biopharmaceutical Manufacturing Services
3.4.2 Strong Revenue Growth 2011-2012
3.4.3 Expanding through New Services
3.4.4 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2013-2023
3.4.5 Boehringer Ingelheim BioXcellence: Revenue Forecast 2013-2023
3.4.6 Boehringer Ingelheim Biopharmaceuticals: Company Insight 2013
3.5 Famar
3.5.1 Famar Is an Expert in Lyophilisation
3.5.2 Famar's Revenue Grows 18% Annually 2007-2011
3.5.3 Expanding European Operations
3.5.4 Further Site Acquisitions Are an Opportunity for Growth 2013-2023
3.5.5 How Will Famar Perform 2013-2023?
3.6 Fareva
3.6.1 Fareva Has 35 Years' Manufacturing Experience
3.6.2 Growth through Acquisitions
3.6.3 Fareva: Contract Manufacturing Market Outlook 2013-2023
3.7 Vetter Pharma
3.7.1 Vetter Is an Injectable Manufacturing Specialist
3.7.2 Vetter Grows in the US and Germany
3.7.3 New Services and Collaborations
3.7.4 Biologics Are an Opportunity for Growth for Vetter 2013-2023
3.7.5 Vetter Outlook: Revenue Forecast 2013-2023
3.8 Almac Group
3.8.1 Almac's Manufacturing Services
3.8.2 Almac Grows Faster than the Market 2007-2011
3.8.3 Almac Adds Capacity in the UK and US
3.8.4 New Services Added 2011-2012
3.8.5 Almac Group: Contract Manufacturing Market Outlook 2013-2023
3.8.6 How Will Almac Group Perform 2013-2023?
3.9 Siegfried
3.9.1 Siegfried's Manufacturing Facilities
3.9.2 Siegfried: Financial Performance 2008-2012
3.9.3 Expanding in Switzerland
3.9.4 Further Regional Expansion 2012-2014
3.9.5 SWOT Analysis 2013-2023
3.9.6 Continued Revenue Growth for Siegfried 2013-2023
3.10 Haupt Pharma
3.10.1 Haupt Manufactures APIs and Finished Dosage Forms
3.10.2 Haupt Pharma's Revenue Grows 17% Annually 2008-2012
3.10.3 Focus on Europe, the US and Japan
3.10.4 Haupt Has Identified Generics as an Opportunity for Growth
3.10.5 Haupt Pharma: Revenue Growth 2013-2023
3.11 Aenova
3.11.1 Aenova Has Manufacturing Capacity of Over 35 Billion Units Annually
3.11.2 Aenova's Revenue Almost Doubled in 2012
3.11.3 Expanding Capacity through Organic Growth and Acquisitions
3.11.4 How Will Aenova Continue Expand in the Contract Manufacturing Market?
3.12 CordenPharma
3.12.1 CordenPharma Has Grown through Acquisitions
3.12.2 CordenPharma: SWOT Analysis 2013-2023
3.13 Delpharm
3.13.1 Finished Dosage Form Manufacturing for Developed Markets
3.13.2 Growing in Western Europe
3.13.3 Delpharm: Outlook 2013-2023
3.13.4 Generics Will Drive Revenue Growth for Delpharm 2013-2023
3.14 Recipharm
3.14.1 Contract Development and Manufacturing Services
3.14.2 Recipharm: Financial Performance 2008-2012
3.14.3 Recipharm Invests in Facility Expansion
3.14.4 Recipharm: Opportunities for Growth 2013-2023
3.14.5 Outlook for Recipharm: Revenue Forecast 2013-2023
3.14.6 Recipharm: Company Insight 2013
3.15 Aesica Pharmaceuticals
3.15.1 Aesica Manufactures APIs and Finished Dosage Forms
3.15.2 Acquisitions Drive Revenue Growth 2007-2011
3.15.3 Partnering with Academia for Innovative Solutions
3.15.4 Growth through Acquisitions and Internal Expansion
3.15.5 Aesica: Opportunities for Expansion 2013-2023
3.15.6 Continued Revenue Growth for Aesica 2013-2023
4. Other Leading Developed Market CMOs 2013
4.1 Catalent Pharma Solutions Is the World's Largest CMO
4.1.1 Catalent: Manufacturing Services and Capabilities
4.1.2 Oral Technologies Drive Steady Revenue Growth 2008-2012
4.1.3 Catalent Is Expanding its Oral Technologies Division
4.1.4 Further Advances in Biopharmaceutical Manufacturing
4.1.5 Adding New Early-Stage Development Services
4.1.6 Catalent: Opportunities for Growth 2013-2023
4.1.7 Catalent: Strong Revenue Growth 2013-2023
4.2 Patheon
4.2.1 Patheon and the Contract Manufacturing Industry
4.2.2 Steady Revenue Growth 2008-2012
4.2.3 Adding New Formulations and Formulation Development Services
4.2.4 Reassessing Manufacturing Capacity
4.2.5 Patheon: Contract Manufacturing Market Outlook 2013-2023
4.2.6 How Will Patheon Perform 2013-2023?
4.2.7 Patheon: Company Insight 2013
4.3 AbbVie Contract Manufacturing
4.3.1 AbbVie Offers Full-Service Contract Manufacturing
4.3.2 Adding New Services for its Customers 2012
4.3.3 Biologics Are an Opportunity for Growth 2013-2023
4.3.4 AbbVie Contract Manufacturing: Company Insight 2013
4.4 Daito Pharmaceutical: Japan's Leading CMO
4.4.1 Daito Has a Portfolio of More than 30 APIs
4.4.2 Daito Grows Faster than the Market 2009-2012
4.4.3 Daito Is Well-Placed for Asian Market Growth
4.4.4 Continued Revenue Growth for Daito 2013-2023
4.5 Pfizer CentreSource
4.5.1 Pfizer Is Well-Placed for Pre-Filled Syringe Growth
4.5.2 Outlook for Pfizer: Revenue Forecast 2013-2023
5. Leading Developed Market API Manufacturers 2013
5.1 Teva API
5.1.1 API Manufacturing Services
5.1.2 Teva API: Financial Performance 2008-2012
5.1.3 Adding Capacity in India
5.1.4 Teva API: Opportunities for Expansion 2013-2023
5.1.5 Outlook for Teva API: Revenue Forecast 2013-2023
5.2 Esteve Química
5.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
5.2.2 Investing to Expand 2004-2012
5.2.3 Esteve Química: SWOT Analysis 2013-2023
5.3 Euticals
5.3.1 Euticals Manufactures More than 200 APIs
5.3.2 Acquisitions Drive Growth 2010-2012
5.3.3 Adding Capacity for Finished Dosage Forms
5.3.4 Asian Expansion Is an Opportunity for Growth 2013-2023
5.3.5 Euticals: Revenue Forecast 2013-2023
5.4 Cambrex
5.4.1 Cambrex and the Contract Manufacturing Industry
5.4.2 Cambrex: Financial Performance 2008-2012
5.4.3 How Can Cambrex Expand in the Pharmaceutical Contract Manufacturing Market?
5.4.4 HPAPIs Will Drive Revenue Growth for Cambrex 2013-2023
5.4.5 Cambrex: Company Insight 2013
6. Leading Chinese Pharmaceuticals Contract Manufacturers 2013
6.1 Shandong Xinhua Pharmaceutical
6.1.1 Experience in APIs and Finished Dosage Forms
6.1.2 Shandong Xinhua: Strong Revenue Growth 2008-2012
6.1.3 Growing through Joint Ventures
6.1.4 Looking to Expand in the US and EU 2013-2023
6.1.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2013-2023
6.2 Zhejiang Hisun Pharmaceutical
6.2.1 API Manufacturing for Markets Worldwide
6.2.2 Zhejiang Hisun's API Revenue Grows 11% Annually 2008-2012
6.2.3 Moving Into International Drug Marketing
6.2.4 Zhejiang Hisun: Opportunities for Growth 2013-2023
6.2.5 Zhejiang Hisun: Strong API Revenue Growth 2013-2023
6.3 Zhejiang Huahai Pharmaceuticals
6.3.1 Zhejiang Huahai Is a Leading Supplier of Pril Products
6.3.2 Zhejiang Huahai: Contract Manufacturing Performance 2011-2012
6.3.3 Expanding in the US Generic Drugs Market
6.3.4 Zhejiang Huahai: SWOT Analysis 2013-2023
7. Leading Indian Pharmaceutical Contract Manufacturers 2013
7.1 Dr. Reddy's Laboratories
7.1.1 API and FDF Manufacturing Services
7.1.2 Dr. Reddy's PSAI: Strong Revenue Growth 2009-2013
7.1.3 Advancing in Complex Drug Manufacturing
7.1.4 Expanding in the European Manufacturing Market
7.1.5 Dr. Reddy's PSAI Division: Revenue Forecast 2013-2023
7.2 Aurobindo Pharma
7.2.1 API Manufacturing Services
7.2.2 Aurobindo Pharma: Steady Revenue Growth 2008-2012
7.2.3 Aurobindo Opens a CRAMS Unit
7.2.4 Aurobindo: Opportunities for Expansion 2013-2023
7.2.5 How Will Aurobindo's Contract manufacturing Division Perform 2013-2023?
7.3 Divis Laboratories
7.3.1 Divis Laboratories and the Contract Manufacturing Industry
7.3.2 Divis Laboratories Revenue Grows 16% Annually 2008-2012
7.3.3 Divis Laboratories: API Manufacturing Outlook 2013-2023
8. Conclusions of Our Study
8.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
8.2 Common Strategies for Growth 2013-2023
8.2.1 High Demand for Biopharmaceutical Manufacturing Services
8.2.2 Investing in Novel Technologies
8.2.3 Outlook for API Manufacturers
8.3 Results from Our Company Survey
List of Tables
Table 1.1 Currency Exchange Rates, 2012
Table 2.1 Benefits and Weaknesses to Outsourcing Pharmaceutical Manufacturing, 2013
Table 2.2 Pharma Contract Manufacturing Market by Sector, 2012
Table 2.3 Pharma Contract Manufacturing Market by Country, 2012
Table 2.4 Pharma Contract Manufacturing: Market and Submarket Forecasts, 2012-2023
Table 2.5 Pharmaceutical Outsourcing Market: CAGRs by Sector, 2012-2023
Table 2.6 Top 30 Pharmaceutical CMOs by Revenue, 2012
Table 3.1 Lonza: Key Facts, 2013
Table 3.2 Lonza: Selected Manufacturing Agreements, 2010-2013
Table 3.3 Lonza Custom Manufacturing: Revenue, 2008-2012
Table 3.4 Antibody-Drug Conjugate: Selected Pipeline Candidates, 2013
Table 3.5 Lonza Custom Manufacturing: SWOT Analysis, 2013-2023
Table 3.6 Lonza Custom Manufacturing: Revenue Forecast, 2012-2023
Table 3.7 Evonik Degussa: Key Facts, 2013
Table 3.8 Evonik Health and Nutrition: R&D and Production Sites by Region, 2013
Table 3.9 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2013-2023
Table 3.10 Royal DSM: Key Facts, 2013
Table 3.11 DSM Pharmaceutical Products: Revenue, 2008-2012
Table 3.12 DSM Pharmaceutical Products: SWOT Analysis, 2013-2023
Table 3.13 DSM Pharmaceutical Products: EBITDA, 2008-2012
Table 3.14 DSM Pharmaceutical Products: Revenue Forecast, 2012-2023
Table 3.15 Boehringer Ingelheim: Key Facts, 2013
Table 3.16 Boehringer Ingelheim BioXcellence: Revenue 2011-2012
Table 3.17 Boehringer Ingelheim BioXcellence: SWOT Analysis, 2013-2023
Table 3.18 Boehringer Ingelheim BioXcellence: Revenue Forecast, 2012-2023
Table 3.19 Famar: Key Facts, 2013
Table 3.20 Famar: Pharmaceutical Manufacturing Facilities, 2013
Table 3.21 Famar: Revenue, 2007-2011
Table 3.22 Famar: SWOT Analysis, 2013-2023
Table 3.23 Famar: Revenue Forecast, 2012-2023
Table 3.24 Fareva: Key Facts, 2013
Table 3.25 Fareva: Pharmaceutical Manufacturing Facilities, 2013
Table 3.26 Fareva Pharmaceutical Manufacturing: SWOT Analysis, 2013-2023
Table 3.27 Vetter Pharma: Key Facts, 2013
Table 3.28 Vetter: Pharmaceutical Manufacturing Facilities, 2013
Table 3.29 Vetter Pharma: SWOT Analysis, 2013-2023
Table 3.30 Vetter Pharma: Revenue Forecast, 2012-2023
Table 3.31 Almac Group: Services and Facilities, 2013
Table 3.32 Almac Group: Key Facts, 2013
Table 3.33 Almac Group: Revenue, 2008-2011
Table 3.34 Almac Group: SWOT Analysis, 2013-2023
Table 3.35 Almac Group: Revenue Forecast, 2012-2023
Table 3.36 Siegfried: Key Facts, 2013
Table 3.37 Siegfried: Revenue, 2008-2012
Table 3.38 Siegfried: Revenue by Sector, 2011-2012
Table 3.39 Siegfried: SWOT Analysis, 2013-2023
Table 3.40 Siegfried: Revenue Forecast, 2012-2023
Table 3.41 Haupt Pharma: Key Facts, 2013
Table 3.42 Haupt Pharma: Services and Facilities, 2013
Table 3.43 Haupt Pharma: Revenue, 2008-2012
Table 3.44 Haupt Pharma: SWOT Analysis, 2013-2023
Table 3.45 Haupt Pharma: Revenue Forecast, 2012-2023
Table 3.46 Aenova: Key Facts, 2013
Table 3.47 Aenova: Facilities, Services and Capacities, 2013
Table 3.48 Aenova: SWOT Analysis, 2013-2023
Table 3.49 CordenPharma: Key Facts, 2013
Table 3.50 CordenPharma: Facilities and Services, 2013
Table 3.51 CordenPharma: SWOT Analysis, 2013-2023
Table 3.52 Delpharm: Key Facts, 2013
Table 3.53 Delpharm: Facilities and Services, 2013
Table 3.54 Delpharm: Revenue, 2008-2012
Table 3.55 Delpharm: SWOT Analysis, 2013-2023
Table 3.56 Delpharm: Revenue by Site, 2011
Table 3.57 Delpharm: Revenue Forecast, 2012-2023
Table 3.58 Recipharm: Key Facts, 2013
Table 3.59 Recipharm: Manufacturing Facilities and Services, 2013
Table 3.60 Recipharm: Revenue, 2008-2012
Table 3.61 Recipharm: Revenue by Customer Type, 2012
Table 3.62 Recipharm: SWOT Analysis, 2013-2023
Table 3.63 Recipharm: Revenue Forecast, 2012-2023
Table 3.64 Aesica Pharmaceuticals: Key Facts, 2013
Table 3.65 Aesica Pharma: Revenue, 2007-2011
Table 3.66 Aesica Pharma: SWOT Analysis, 2013-2023
Table 3.67 Aesica Pharma: Revenue Forecast, 2012-2023
Table 4.1 Catalent Pharma Solutions: Key Facts, 2013
Table 4.2 Catalent: Manufacturing Sites by Region, 2013
Table 4.3 Catalent: Revenue, 2008-2012
Table 4.4 Catalent: SWOT Analysis, 2013-2023
Table 4.5 Catalent: Revenue Forecast, 2012-2023
Table 4.6 Patheon: Key Facts, 2013
Table 4.7 Patheon: Revenue, 2008-2012
Table 4.8 Patheon: SWOT Analysis, 2013-2023
Table 4.9 Patheon: Revenue Forecast, 2012-2023
Table 4.10 AbbVie Contract Manufacturing: Key Facts, 2013
Table 4.11 AbbVie Contract Manufacturing: Facilities and Services, 2013
Table 4.12 AbbVie Contract Manufacturing: SWOT Analysis, 2013-2023
Table 4.13 Daito Pharmaceutical: Key Facts, 2013
Table 4.14 Daito Pharmaceutical: Revenue, 2008-2012
Table 4.15 Daito Pharmaceutical: SWOT Analysis, 2013-2023
Table 4.16 Daito Pharmaceutical: Revenue Forecast, 2012-2023
Table 4.17 Pfizer CentreSource: Key Facts, 2013
Table 4.18 Pfizer CentreSource: Revenue, 2010-2012
Table 4.19 Pfizer CentreSource: SWOT Analysis, 2013-2023
Table 4.20 Pfizer CentreSource: Revenue Forecast, 2012-2023
Table 5.1 Teva API: Key Facts, 2013
Table 5.2 Teva API: Site Acquisitions, 1980-2011
Table 5.3 Teva API: Revenue, 2008-2012
Table 5.4 Teva API: SWOT Analysis, 2013-2023
Table 5.5 Teva API: Revenue Forecast, 2012-2023
Table 5.6 Esteve Química: Key Facts, 2013
Table 5.7 Esteve Química: SWOT Analysis, 2013-2023
Table 5.8 Euticals: Key Facts, 2013
Table 5.9 Euticals: Facilities and Key Products, 2013
Table 5.10 Euticals: Cumulative Regulatory Filings by Region, 2013
Table 5.11 Euticals: Revenue, 2010-2012
Table 5.12 Euticals: SWOT Analysis, 2013-2023
Table 5.13 Euticals: Revenue Forecast, 2012-2023
Table 5.14 Cambrex: Key Facts, 2013
Table 5.15 Cambrex: Facilities and Services, 2013
Table 5.16 Cambrex: Revenue, 2008-2012
Table 5.17 Cambrex: SWOT Analysis, 2013-2023
Table 5.18 Cambrex: Revenue Forecast, 2012-2023
Table 6.1 Shandong Xinhua Pharmaceutical: Key Facts, 2013
Table 6.2 Shandong Xinhua: Annual Manufacturing Capacity, 2013
Table 6.3 Shandong Xinhua: Revenue, 2008-2012
Table 6.4 Shandong Xinhua: Revenue by Region, H1 2011-2012
Table 6.5 Shandong Xinhua: SWOT Analysis, 2013-2023
Table 6.6 Shandong Xinhua: Revenue Forecast, 2012-2023
Table 6.7 Zhejiang Hisun Pharmaceutical: Key Facts, 2013
Table 6.8 Zhejiang Hisun Pharmaceutical Production: Revenue, 2009-2012
Table 6.9 Zhejiang Hisun Pharmaceutical Production: SWOT Analysis, 2013-2023
Table 6.10 Zhejiang Hisun Pharmaceutical Production: Revenue Forecast, 2012-2023
Table 6.11 Zhejiang Huahai Pharmaceutical: Key Facts, 2013
Table 6.12 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2013-2023
Table 7.1 Dr. Reddy's Laboratories: Key Facts, 2013
Table 7.2 Dr. Reddy's: Cumulative Regulatory Filings by Region, 2013
Table 7.3 Dr. Reddy's PSAI Division: Revenue, 2009-2013
Table 7.4 Dr. Reddy's PSAI Division: SWOT Analysis, 2013-2023
Table 7.5 Dr. Reddy's PSAI Division: Revenue Forecast, 2012-2023
Table 7.6 Aurobindo Pharma: Key Facts, 2013
Table 7.7 Aurobindo Pharma: Contract Manufacturing Revenue, 2008-2012
Table 7.8 Aurobindo Pharma Contract Manufacturing: SWOT Analysis, 2013-2023
Table 7.9 Aurobindo Contract Manufacturing: Revenue Forecast, 2012-2023
Table 7.10 Divis Laboratories: Key Facts, 2013
Table 7.11 Divis Laboratories: Cumulative Regulatory Filings by Region, 2013
Table 7.12 Divis Laboratories: Revenue, 2008-2012
Table 7.13 Divis Laboratories: SWOT Analysis, 2013-2023
Table 7.14 Divis Laboratories: Revenue Forecast, 2012-2023
Table 8.1 Top Five Developed and Emerging Market CMOs: Revenue Growth Comparison, 2008-2012
Table 8.2 Leading CMOs: Combined Revenue Forecast, 2013-2023
Table 8.3 CMO Insight: Current and Future Customer Demands
Table 8.4 CMO Insight: Trends in Drug Development Impacting CMOs 2013-2023
List of Figures
Figure 2.1 Selected Services Offered by CMOs, 2013
Figure 2.2 Pharma Contract Manufacturing Market by Sector, 2012
Figure 2.3 Pharma Contract Manufacturing Market by Country, 2012
Figure 2.4 Pharma Contract Manufacturing: Market Forecast, 2012-2023
Figure 2.5 Pharma Contract Manufacturing Market: Drivers and Restraints, 2013-2023
Figure 2.6 Top 30 Pharmaceutical CMOs by Revenue, 2012
Figure 3.1 Lonza Custom Manufacturing: Revenue, 2008-2012
Figure 3.2 Lonza Custom Manufacturing: Revenue Forecast, 2012-2023
Figure 3.3 Evonik Health and Nutrition: R&D and Production Sites by Region, 2013
Figure 3.4 DSM Pharmaceutical Products: Revenue, 2008-2012
Figure 3.5 DSM Pharmaceutical Products: EBITDA, 2008-2012
Figure 3.6 DSM Pharmaceutical Products: Revenue Forecast, 2012-2023
Figure 3.7 Boehringer Ingelheim BioXcellence: Revenue 2011-2012
Figure 3.8 Boehringer Ingelheim BioXcellence: Revenue Forecast 2013-2023
Figure 3.9 Famar: Revenue, 2007-2011
Figure 3.10 Famar: Revenue Forecast, 2012-2023
Figure 3.11 Vetter Pharma: Revenue Forecast, 2012-2023
Figure 3.12 Almac Group: Revenue, 2008-2011
Figure 3.13 Almac Group: Revenue Forecast, 2012-2023
Figure 3.14 Siegfried: Revenue, 2008-2012
Figure 3.15 Siegfried: Revenue Forecast, 2012-2023
Figure 3.16 Haupt Pharma: Revenue, 2008-2012
Figure 3.17 Haupt Pharma: Revenue Forecast, 2012-2023
Figure 3.18 Delpharm: Revenue, 2008-2012
Figure 3.19 Delpharm: Revenue by Site, 2011
Figure 3.20 Delpharm: Revenue Forecast, 2012-2023
Figure 3.21 Recipharm: Revenue, 2008-2012
Figure 3.22 Recipharm: Revenue by Customer Type, 2012
Figure 3.23 Recipharm: Revenue Forecast, 2012-2023
Figure 3.24 Aesica Pharma: Revenue, 2007-2011
Figure 3.25 Aesica Pharma: Revenue Forecast, 2012-2023
Figure 4.1 Catalent: Manufacturing Sites by Region, 2013
Figure 4.2 Catalent: Revenue, 2008-2012
Figure 4.3 Catalent: Revenue Forecast, 2012-2023
Figure 4.4 Patheon: Revenue, 2008-2012
Figure 4.5 Patheon: Revenue Forecast, 2012-2023
Figure 4.6 Daito Pharmaceutical: Revenue, 2008-2012
Figure 4.7 Daito Pharmaceutical: Revenue Forecast, 2012-2023
Figure 4.8 Pfizer CentreSource: Revenue, 2010-2012
Figure 4.9 Pfizer CentreSource: Revenue Forecast, 2012-2023
Figure 5.1 Teva API: Revenue, 2008-2012
Figure 5.2 Teva API: Revenue Forecast, 2012-2023
Figure 5.3 Euticals: Revenue, 2010-2012
Figure 5.4 Euticals: Revenue Forecast, 2012-2023
Figure 5.5 Cambrex: Revenue, 2008-2012
Figure 5.6 Cambrex: Revenue Forecast, 2012-2023
Figure 6.1 Shandong Xinhua: Revenue, 2008-2012
Figure 6.2 Shandong Xinhua: Revenue by Region, H1 2012
Figure 6.3 Shandong Xinhua: Revenue Forecast, 2012-2023
Figure 6.4 Zhejiang Hisun Pharmaceutical Production: Revenue, 2009-2012
Figure 6.5 Zhejiang Hisun Pharmaceutical Production: Revenue Forecast, 2012-2023
Figure 7.1 Dr. Reddy's PSAI Division: Revenue, 2009-2013
Figure 7.2 Dr. Reddy's PSAI Division: Revenue Forecast, 2012-2023
Figure 7.3 Aurobindo Pharma: Contract Manufacturing Revenue, 2008-2012
Figure 7.4 Aurobindo Contract Manufacturing: Revenue Forecast, 2012-2023
Figure 7.5 Divis Laboratories: Revenue, 2008-2012
Figure 7.6 Divis Laboratories: Revenue Forecast, 2012-2023
Figure 8.1 Top Five Developed and Emerging Market CMOs: Revenue Growth Comparison, 2008-2012
To view free sample pages of this report please click here
Abbott
AbbVie
AbbVie Contract Manufacturing
Abic (part of Teva)
Activa Capital
Aegerion Pharmaceuticals
Aenova
Aerofarm (part of Fareva)
Aesica Pharmaceuticals
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM) [France]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agennix
Ajinomoto OmniChem
AlgoNomics (part of Lonza)
Alliance Medical Products (part of Siegfried)
Almac Group
Alpharma
Amgen
Apexigen
Aptuit
Archimica (part of Euticals)
Arecor
Astellas Pharma
AstraZeneca
Athera Biotechnologies
Aurobindo Pharma
AuroSource (part of Aurobindo Pharma)
Avalanche Biotechnologies
Banner Pharmacaps (part of Patheon)
BaroFold
Barr-Pliva (part of Teva)
BASF
Bayer
BC Partners
Beijing Double-Crane Pharmaceutical (BDCP)
Bellwyck Packaging Solutions
Bend Research
Bentley Pharma (part of Teva)
Biogal
Bionomics
Blackstone Group
Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals
Bridgepoint
Bristol-Myers Squibb
Britest
Cambrex
Cardinal Health
Catalent (Shanghai) Clinical Trial Supplies Co
Catalent Pharma Solutions
Celladon
Celldex Therapeutics
CEVEC Pharmaceuticals
Chemo
Chemtrix
China National Pharmaceutical Group (Sinopharm)
Chirotech Technology (part of Dr. Reddy's Laboratories)
Cleveland BioLabs
Cobra Biologics Holding
CordenPharma (part of ICIG)
CPM ContractPharma (part of Aenova)
CTC Bio
Daiichi Sankyo
Daito Pharmaceutical
DecImmune Therapeutics
Delmas Perfusion
Delpharm
DiFUSION Technologies
Divis Laboratories
Dr. Reddy's Laboratories
DSM Sinochem Pharmaceuticals
Durham University
Eclipse Therapeutics (part of Bionomics)
Eindhoven University of Technology
Eisai
Eli Lilly
EmulTech
Enobia Pharma (now Alexion Pharmaceuticals)
Enzon Pharmaceuticals
Esteve
Esteve Química (part of Esteve)
Euro Vital Pharma (part of Aenova)
European Medicines Agency (EMA)
Euticals
Evonik Degussa (part of Evonik Industries)
Evonik Industries
Excella (part of Fareva)
Excelvision (part of Fareva)
Exelixis
Famar
Fareva
Farma Lepori (part of Angelini Group)
Farmaclair (part of Fareva)
Farmaprojects
Farmea (part of Fareva)
Food and Drug Administration (FDA) [US]
Frazier Healthcare
Fuyang Xinghai Investment
Genentech (part of Roche)
Générique Même Médicament (GEMME) [France]
Genzyme (part of Sanofi)
Gilead Sciences
GSK
Gyma Laboratories of America
Haupt Pharma
Health and Safety Executive (HSE) [UK]
Health Canada
Hisun-Pfizer Pharmaceuticals
Human Genome Sciences (part of GSK)
ICI (Imperial Chemical Industries)
Immune Pharmaceuticals
Indoco Remedies
Instituto de Angeli (part of Fareva)
Intellect Neurosciences
International Chemical Investors Group (ICIG)
Invita
Ipsen
Ivax API (part of Teva)
J&J
JK Pharmaceutical
Laboratoire Aguettant
Laboratoires Besins
Lanxess
Lonza
Marinopoulos Group
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck KGaA
Mesoblast
Molecular Partners
Mylan
National Institutes of Health (NIH) [US]
National Institutes of Health Center for Regenerative Medicine (NIH CRM) [US]
New Jersey Institute of Technology
Novartis
Novasep
OctoPlus (part of Dr. Reddy's Laboratories)
OmniChem (part of Ajinomoto OmniChem)
OncoMed Pharmaceuticals
Osiris Therapeutics
Otsuka Pharmaceutical
Pantec
Paranta Biosciences
Parexel
Patheon
Perrigo
PFC (now Teva PFC)
Pfizer
Pfizer CentreSource (part of Pfizer)
Pharmintraco
Piramal Pharma Solutions (part of Piramal Enterprises)
Plantex (part of Teva)
Poli Industria Chimica (part of Euticals)
Procaps
Prosintex Química
R5 Pharmaceuticals (part of Aesica Pharmaceuticals)
RAG
Ranbaxy Laboratories (part of Daiichi Sankyo)
Recepta Biopharma
Recipharm
Redwood Bioscience
Respirics (part of Zhejiang Hisun Pharmaceutical)
Roche
Royal DSM
Saltigo (part of Lanxess)
Sandoz (part of Novartis)
Sanofi
Sanwa Kagaku Kenkyusho Co
ScinoPharm
Seattle Genetics
Sentry BioPharma Services
Servier
Shandong Xinhua Pharmaceutical (Europe) (part of Shandong Xinhua Pharmaceutical)
Shandong Xinhua Pharmaceutical Co
Shanghai Pharmaceutical Co
ShangPharma
Shire
Sicor Biotech (part of Teva)
Siegfried
Sigmar Italia (part of Fareva)
Silverfleet Capital
Sinochem
SkyePharma
Softigel (part of Procaps)
State Food and Drug Administration (SFDA) [China]
SurModics (part of Evonik Industries)
Swedbank
SwissCo Services (part of Aenova)
Synkem
Takeda Pharmaceutical Company
Temmler Group (part of Aenova)
Temmler Ireland (part of Aenova)
Temmler Italia (part of Aenova)
Temmler Pharma (part of Aenova)
Temmler Werke (part of Aenova)
Tessenderlo Group
Teva API
Teva Pharmaceutical Industries
Théramax (part of Teva)
Thermo Fisher Scientific
Tianjin Tianyo Pharmaceuticals
Tianma Tianji
UCB
UMN Pharma
UniQure
University of Bradford
University of Leeds
Valdepharm (part of Fareva)
Vetter Pharma
ViroPharma
Vivante GMP Solutions (part of Lonza)
VTU Technology
Wanhuai Beijing Double-Crane Pharmaceutical (part of BDCP)
West Pharmaceutical Services
Xinhua Pharmaceutical (Gaomi) Company (part of Shandong Xinhua Pharmaceutical)
XOMA
Yiwu Huayi Investment
Zenara Pharmaceuticals
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology
Zibo Xinhua-Perrigo Pharmaceutical Company
To view free sample pages of this report please click here
